Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 718 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Recurrent Childhood Glioblastoma Clear all
Completed Phase 2 Interventional Results available

AMG 102 and Avastin for Recurrent Malignant Glioma

NCT01113398
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma
Interventions
AMG 102, Avastin
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma

NCT05362409
View directory record Official record
Conditions
High Grade Glioma
Interventions
5 Aminolevulinic Acid, CV01-delivered ultrasound
Drug · Device
Lead sponsor
Alpheus Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
St Louis, Missouri • Amherst, New York • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Jul 21, 2026, 9:57 AM EDT
Suspended Phase 2 Interventional

Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma

NCT05183204
View directory record Official record
Conditions
Glioblastoma
Interventions
Paxalisib, Metformin, Ketogenic Diet
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain

NCT00003348
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine, carmustine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Jul 21, 2026, 9:57 AM EDT
Terminated Phase 2 Interventional

Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy

NCT02047214
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
TPI 287, Bevacizumab
Drug
Lead sponsor
Cortice Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Jul 21, 2026, 9:57 AM EDT
Recruiting Phase 2 Interventional

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

NCT07301268
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4, Progressive Glioblastoma, Progressive Gliosarcoma, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Resectable Astrocytoma, Resectable Glioblastoma
Interventions
Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pembrolizumab, Surgical Procedure
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 21, 2026, 9:57 AM EDT
Not yet recruiting Phase 1 Interventional

A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

NCT07579208
View directory record Official record
Conditions
Phase 1, NK Cell, IL13Ra, EGFRvIII, Chimera Antigen Receptor (CAR), NR3C1, Recurrent Glioblastoma
Interventions
NK Cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas

NCT00612638
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temodar, O6-BG, and Irinotecan
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma

NCT00329719
View directory record Official record
Conditions
Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
Interventions
Conventional Surgery, Laboratory Biomarker Analysis, Sorafenib Tosylate, Temsirolimus
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
190
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Hartford, Connecticut + 118 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Early Phase 1 Interventional

Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma

NCT00864864
View directory record Official record
Conditions
Glioblastoma, Brain Tumor
Interventions
Sunitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Jul 21, 2026, 9:57 AM EDT
Active, not recruiting Early Phase 1 Interventional

Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas

NCT06824662
View directory record Official record
Conditions
Glioblastoma WHO Grade IV
Interventions
Quisinostat
Drug
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jul 21, 2026, 9:57 AM EDT
Terminated Phase 1 Interventional

Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme

NCT01122888
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Solid Neoplasm, Recurrent Adult Brain Neoplasm
Interventions
Cilengitide, Clinical Observation, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors

NCT00002754
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
Interventions
monoclonal antibody Me1-14 F(ab')2
Biological
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

NCT01576666
View directory record Official record
Conditions
Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors, Metastatic Breast Cancer, Advanced Pancreatic Adenocarcinoma, Metastatic Colorectal Cancer, Recurrent Glioblastoma Multiforme, Gastric Cancer, Gastroesophageal Junction Cancer, Triple Negative Metastatic Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Interventions
LDE225, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 2 Interventional

Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors

NCT00179803
View directory record Official record
Conditions
Glioblastoma, Astrocytoma, Pineoblastoma, Rhabdoid Tumor, Supratentorial Neoplasms
Interventions
Stem Cell Transplant
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
18 Months to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Jul 21, 2026, 9:57 AM EDT
Terminated Not applicable Interventional Results available

Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)

NCT01925573
View directory record Official record
Conditions
RECURRENT GLIOBLASTOMA, Brain Tumor
Interventions
Optune(NOVOTTF-100A)
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
22 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 2 Interventional

GW572016 to Treat Recurrent Malignant Brain Tumors

NCT00107003
View directory record Official record
Conditions
Glioma, Brain Tumor, Glioblastoma Multiforme, GBM, Gliosarcoma, GS
Interventions
lapatinib ditosylate, Adjuvant therapy, Conventional surgery, Neoadjuvant therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

NCT03914742
View directory record Official record
Conditions
IDH1 Mutation, IDH2 Mutation, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
Interventions
PARP Inhibitor BGB-290, Temozolomide, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jul 21, 2026, 9:57 AM EDT
Active, not recruiting Phase 1 Interventional

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

NCT05739942
View directory record Official record
Conditions
Newly Diagnosed and Recurrent Glioblastoma
Interventions
[177Lu]Lu-NeoB, [68Ga]Ga-NeoB, Temozolomide
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Not applicable Interventional Results available

FMISO PET Study of Glioblastoma

NCT02076152
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
FMISO PET, MRI, Bevacizumab, CCNU
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jul 21, 2026, 9:57 AM EDT
Suspended Phase 2 Interventional

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

NCT06325683
View directory record Official record
Conditions
Progressive Glioblastoma, Recurrent Glioblastoma
Interventions
Biopsy Procedure, Biospecimen Collection, Lomustine, Magnetic Resonance Imaging, Nivolumab, Relatlimab, Surgical Procedure
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
325
States / cities
Jonesboro, Arkansas • Auburn, California • Duarte, California + 252 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 21, 2026, 9:57 AM EDT
Recruiting Early Phase 1 Interventional

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

NCT06613841
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, Glioblastoma Multiforme of Brain
Interventions
Fluciclovine F18
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas

NCT00412542
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioma
Interventions
Thalidomide, CPT-11, MRI Scan, Quantitative Sensory Tests (QST)
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Jul 21, 2026, 9:57 AM EDT
Completed Phase 1 Interventional Results available

Nivolumab With DC Vaccines for Recurrent Brain Tumors

NCT02529072
View directory record Official record
Conditions
Malignant Glioma, Astrocytoma, Glioblastoma
Interventions
nivolumab, DC
Drug · Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Jul 21, 2026, 9:57 AM EDT